Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Langer on Assessing Patient Populations in Trials

October 4th 2011

Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials

Making a Mark in Lung Cancer: An Interview With Roy S. Herbst, MD, PhD

October 4th 2011

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

Oncogenic Signaling of the EGFR: Familiar Target Faces New Questions

October 3rd 2011

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

Dr. Mills Explains the Vulnerability of Cancer Cells

October 3rd 2011

Dr. Gordon Mills from MD Anderson Cancer Center Explains the Vulnerability of Cancer Cells

Dr. Morrow Describes the ACOSOG Z11 Trial

September 30th 2011

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Describes the ACOSOG Z11 Trial

Dr. Wakelee on Adjuvant Therapy Predictive Markers

September 30th 2011

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Dr. Mills on the Shifts Towards Personalized Medicine

September 29th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Dr. Dixon on Systems Biology for Combination Therapy

September 28th 2011

Dr. Michael Dixon from University of Edinburgh on Systems Biology Determining Therapy Combinations

Dr. Scagliotti on the Benefits of EGFR Targeted Therapy

September 27th 2011

Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits

Dr. Ellis on Genome Forward Breast Cancer Treatment

September 26th 2011

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer

September 25th 2011

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

Cell or Sell: That Is the Question

September 23rd 2011

In vitro cell manipulation has unleashed the therapeutic potential of human cells.

Dr. Tripathy Discusses Breast Carcinoma Heterogeneity

September 20th 2011

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Li Describes the Future of Lung Cancer Therapy

September 19th 2011

Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy

Dr. Rugo on VEGF-A as an Avastin Response Predictor

September 16th 2011

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. Scagliotti Discusses EGFR Mutations in NSCLC

September 16th 2011

Dr. Giorgio Scagliotti from University of Turin Discusses EGFR Mutations in non-small cell lung cancer

Dr. Dixon on Letrozole With Pathway Inhibitors

September 15th 2011

Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors

Dr. O'Shaughnessy on the Future of TNBC Treatment

September 15th 2011

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment

Dr. Ellis on Hopeful ER+/HER2- Breast Cancer Paradigms

September 14th 2011

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

Dr. Scagliotti on Tailored Treatment & Host Genomics

September 13th 2011

Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome